Megacard

Megacard Uses, Dosage, Side Effects, Food Interaction and all others data.

Megacard are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Megacard are currently marketed in the US, EU, and many other regions under the brand name Lovaza.

Megacard reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C).

Megacard
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Megacard
Generic	Omega-3-acid ethyl esters
Omega-3-acid ethyl esters Other Names	Omega-3 fatty acid ethyl esters, Omega-3-acid ethyl esters
Type	Capsule
Protein binding	Because omega-3-acid ethyl esters are rapidly hydrolysed and incorporated into other processes and structures, protein binding data is scarce. However, most of EPA is bound to plasma protein.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Mission Pharmaceuticals
Available Country	Pakistan
Last Updated:	September 19, 2023 at 7:00 am

Uses

Megacard is a mixture of fatty acids used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.

Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).

Megacard is also used to associated treatment for these conditions: Severe Hypertriglyceridemia

How Megacard works

Megacard reduce triglyceride production by the liver but this mechanism is not well understood. Megacard inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Megacard also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C.

Toxicity

In rats, omega-3-acid ethyl esters are not mutagenic or clastogenic and do not lead to impairment of fertility.

Safety in human pregnancy have not been performed, however an embryocidal effect was seen in rats force fed 7 times the maximum recommended human dose. The risk and benefit of treatment during pregnancy should be weighed before deciding on treatment.

Animal studies in lactating rats have shown excretion of omega-3-acid ethyl esters at concentrations 6 to 14 times higher than in the serum of the mother, however the effects of this excretion on a mother or child have not been established.

Safety and effectiveness in pediatric patients has not been established.

There appear to be no differences in the safety and efficacy in patients above or below 60 years of age based on limited data.

Food Interaction

Take with a full glass of water.
Take with food. Take with food to reduce gastrointestinal disturbance.

Volume of Distribution

82 ± 56L

Elimination Route

Megacard are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible.